Trulieve Cannabis Subordinate Voting Shares Financial Ratios
NYSE: TRLVHealth Care Medicinal Chemicals and Botanical Products USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Trulieve Cannabis Subordinate Voting Shares ratio analysis
Trulieve Cannabis Subordinate Voting Shares earned a net margin of -10.3% in FY 2025, up from -13.5% a year earlier. Gross margin was 60.2% compared with a median of 60.6% over the prior 6 years. Return on equity reached -10.7%, meaning Trulieve Cannabis Subordinate Voting Shares generated -0.11 dollars of profit for every dollar of shareholders' equity.
Debt-to-equity stood at 0.08 versus 0.09 the year before, and the current ratio was 4.43. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Trulieve Cannabis Subordinate Voting Shares financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| P/E ratio (at fiscal year end) | — | — | — | — | 123.86 | 59.66 | 24.51 |
| Price / sales | 1.41 | 0.91 | 0.87 | 1.17 | 3.89 | 6.89 | 4.92 |
| Price / book | 1.46 | 0.86 | 0.70 | 0.74 | 1.69 | 8.02 | 9.35 |
| Gross margin | 60.2% | 60.3% | 52.1% | 56.6% | 60.8% | 74.1% | 75.9% |
| Operating margin | 12.1% | 8.2% | -19.6% | 4.1% | 21.9% | 41.9% | 44.8% |
| Net margin | -10.3% | -13.5% | -47.2% | -20.7% | 1.9% | 12.1% | 21.0% |
| Free cash flow margin | 19.4% | 12.5% | 14.3% | -11.6% | -28.2% | -0.1% | -20.9% |
| Return on equity (ROE) | -10.7% | -12.9% | -37.8% | -13.1% | 0.8% | 14.1% | 40.0% |
| Return on assets (ROA) | -4.5% | -5.6% | -19.5% | -7.4% | 0.5% | 7.8% | — |
| Debt / equity | 0.08 | 0.09 | 0.08 | 0.05 | 0.00 | 0.01 | — |
| Current ratio | 4.43 | 4.37 | 4.16 | 2.82 | 3.10 | 3.43 | — |
| Revenue growth | -0.4% | 5.1% | -7.3% | 30.7% | 78.7% | 106.3% | — |
| EPS growth | — | — | — | -552.4% | -60.4% | 15.2% | — |